Browse > Article

Antinociceptive Effect of the Intrathecal Phosphodiesterase Inhibitor, Zaprinast, in a Rat Formalin Test  

Heo, Burn Young (Department of Anesthesiology and Pain Medicine, Medical School, Chonnam National University)
Kim, Chang Mo (Department of Anesthesiology and Pain Medicine, Medical School, Chonnam National University)
Jeong, Sung Tae (Department of Anesthesiology and Pain Medicine, Medical School, Chonnam National University)
Kim, Seok Jai (Department of Anesthesiology and Pain Medicine, Medical School, Chonnam National University)
Choi, Jeong II (Department of Anesthesiology and Pain Medicine, Medical School, Chonnam National University)
Yoon, Myung Ha (Department of Anesthesiology and Pain Medicine, Medical School, Chonnam National University)
Publication Information
The Korean Journal of Pain / v.18, no.2, 2005 , pp. 99-106 More about this Journal
Abstract
Background: Cyclic guanosine monophosphate (cGMP) and opioid receptors are involved in the modulation of nociception. Although the opioid receptors agonists are active in pain, the effect of an phospodiesterase inhibitor (zaprinast) for increasing the level of cGMP has not been thoroughly investigated at the spinal level. This study examined the effects of intrathecal zaprinast and morphine in a nociceptive test and we also examined the nature of the pharmacological interaction after the coadministration of zaprinast with morphine. The role of the nitric oxide (NO)-cGMP-potassium channel pathway on the effect of zaprinast was further clarified. Methods: Catheters were inserted into the intrathecal space of male SD rats. For the induction of pain, $50{\mu}l$ of 5% formalin solution was applied to the hindpaw. Isobolographic analysis was used for the evaluation of the drug interaction between zaprinast and morphine. Furthermore, NO synthase inhibitor ($_L-NMMA$), guanylyl cyclase inhibitor (ODQ) or a potassium channel blocker (glibenclamide) were intrathecally administered to verify the involvement of the NO-cGMP- potassium channel pathway on the antinociception effect of zaprinast. Results: Both zaprinast and morphine produced an antinociceptive effect during phase 1 and phase 2 in the formalin test. Isobolographic analysis revealed a synergistic interaction after the intrathecal administration of the zaprinast-morphine mixture in both phases. Intrathecal $_L-NMMA$, ODQ and glibenclamide did not reverse the antinociception of zaprinast in either phase. Conclusions: These results suggest that zaprinast, morphine and the mixture of the two drugs are effective against acute pain and they facilitated pain state at the spinal level. Thus, the spinal combination of zaprinast with morphine may be useful for the management of pain. However, the NO-sensitive cGMP-potassium channel pathway did not contribute to the antinocieptive mechanism of zaprinast in the spinal cord.
Keywords
antinociception; interaction; morphine; NO-cGMP-potassium channel pathway; spinal cord; zaprinast;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ferreira SH, Nakamura M: Prostaglandin hyperalgesia, a cAMP/Ca2+ dependent process. Prostaglandins 1979; 18: 179-90.
2 Mixcoatl-Zecuatl T, Aguirre-Banuelos P, Granados-Soro V: Sildenafil produces antinociceptionand increases morphine antinociception in the formalin test. Eur J Pharmacol 2000; 400: 81-7.
3 Paril CS,Jain NK, Singh A, Kulkarni SK: Modulatory effect of cycleoxygenaseinhibitors on sildenafil-induced antinociception. Pharmacology 2003; 69: 183-9.
4 BeavoJA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725-48.
5 Yamazumi I, Okuda T, Koga Y: Involvement of potassium channels in spinal antinociceptions induced by fentanyl, clonidine and bethanechol in rats. ]pn ] Pharmacol 2001; 87: 268-76.
6 elicits peripheral antinociception by activation of the Larginine/ nitric oxide/cyclic GMP pathway. Eur ] Pharmacol 2002; 454: 19-23-
7 Yoon MH, Choi ]1: Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. Anesthesiology 2003; 99: 701-7.
8 Tallarida R], Murray RB: Manual of pharmacologic calculations with computer programs. 2nd ed. New York, Springer-Verlag. 1987, pp 1-95.
9 Beavo ]A, Reifsnyder DH: Primary sequence of cyclic nucleotide phosphodiesterase isozyrnes and the design of selective inhibitors. Trends Pharmacal Sci 1990; 11: 150-5.
10 Przesmycki K, Dzieciuch ]A, Czuczwar S], Kleinrok Z: Isobolographic analysis of interaction between intrathecal morphine and clonidine in the formalin test in rats. Eur] Pharmacol 1997; 337: 11-7.
11 Berenbaum MC: What is synergy? Pharmacal Rev 1989; 41: 93-141.
12 Yamamoto T, Yaksh TL: Comparison of the antinociceptive effects of pre- and posttreatment with intrathecal morphine and MK801, an NMDA antagonist, on the formalin test in the rat. Anesthesiology 1992; 77: 757-63.
13 Jain NK, Kulkarni SK: L-NAME, a nitric oxide synthase inhibitor, modulates cholinergic antinociception. Methods Find Exp Clin Pharmacol 1999; 21: 161-5.
14 Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 17: 1031-6.
15 Nathan C: Inducible nitric oxide synthase: what difference does it make' J Clin Invest 1997; 100: 2417-23.
16 Soares AC, Leite R, Tarsuo MA, Duarte ID: Activation of ATPsensitive K( +) channels: mechanism of peripheral antinociceptive action of the nitric oxide donor, sodium nitroprusside. Eur J Pharmacol 2000; 400: 67-71.
17 Rodrigues AR, Duarte ID: The peripheral antinociceptive effect induced by morphine is associated with ATP-sensitive K( +) channels. Br ] Pharmacol 2000; 129: 110-4.
18 Moncada S, Higgs A: The Larginine-nitric oxide pathway. N Engl ] Med 1993; 329: 2002-12.
19 Bulurcu F, Dogrul A, Oguz Guc M: The involvement of nitric oxide in the analgesic effect of ketamine. Life Sciences 2002; 71: 841-53.
20 Kawabata A, Fukuzumi Y, Fukushima Y, Takagi H: Antinociceptive effect of L-arginine on the carrageenin-induced hyperalgesia of the rat: possible involvement of central opioidergic systems. Eur J Pharmacal 1992; 218: 153-8.
21 Sousa AM, Prado WA: The dual effect of a nitric oxide donor in nociception. Brain Res 2001; 897: 9-19.
22 Granados-Soto V, Rufino MO, Gomes Lopes LO, Ferreira SH: Evidence for the involvement of the nitric oxide-cGMP pathway in the antinociception of morphine in the formalin test. Eur ] Pharmacol 1997; 340: 177-80.
23 Ortiz MI, Torres-Lopez ]E, Cast~neda-Hernandez G, Rosas R, VidalCantu GC, Granados-Soto V: Pharmacological evidence for the activation of K( +) channels by diclofenac. Eur ] Pharmacol 2002; 438: 85-91.
24 Malmberg AB, Yaksh TL: Pharmacology of the spinal action of ketorolac, morphine, ST-91, U50488H, and L-PIA on the formalin test 1993; 79: 270-81.
25 Durate ID, Lorenzetti BB, Ferreira SH: Peripheral analgesia and activation of the nitric oxide-cyclicGMP pathway. Eur] Pharmacol 1990; 186: 289-93.
26 Ortiz MI, Granados-Soto V, Castaneda-Hernandez G: The NOcGMP-K + channel pathway participates in the anrinociceptive effect of diclofenac, bur not of indomethacin. Pharmacal Biochem Behav 2003; 76: 187-95.
27 Minneman KP, Iversen IL: Enkephalin and opiate narcotics increase cyclic GMP accumulation in slices of rat neostriatum. Nature 1976; 262: 313-4.
28 Jain NK, Patil CS, Singh A, Kulkarni SK: Sildenafil, a phosphodiesterase-5 inhibitor, enhances the antinociceptive effect of morphine. Pharmacology 2003; 67: 150-6.
29 Pyne NJ, Arshavsky V, Lochhead A: cGMP signal termination. Biochem Soc Trans 1996; 24: 1019-22.
30 Jain NK, Pati! CS, Singh A, Kulkarni SK: Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Brain Res 2001; 909: 170-8.
31 Moreland RB, Goldstein II, Kim NN, Traish A: Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor. Trends Endocrinol Metab 1999; 10: 97-104.
32 Cunha FQ, Teixeira MM, Ferreira SH: Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia. Br ] Pharmacal 1999; 127: 671-8.
33 Asomoza-Espinosa R, Alonso-Lopez R, Mixcoatl-Zecuatl T, AguirreBanuelosP, Tortes-Lopez JE, Granados-Soto V: Sildenafil increases diclofenac antinociception in the formalin test. Eur J Pharmacol 2001; 418: 195-200.
34 Deguchi T: Endogenous activating factor for guanylate cyclase in synaptosomal-soluble fraction of rat brain. ] Bioi Chern 1977; 252: 7617-9.
35 Islas-Cadena M, Aguirre-Banuelos P, Granados-Soto V: Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceprive effect of nirnesulide. ] Pharmacol Toxicol Methods 1999; 42: 87-92.
36 Salter M, Strijbos P], Neale S, Duffy C, Follenfant RL, Garthwaite ]: The nitric oxide-cyclic GMP parhway is required for nociceptive signalling ar specific loci within the somatosensory parhway. Neuroscience 1996; 73: 649-55.
37 Ferreira SH, Duarte ID, Lorenzetti BB: The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. Eur] Pharmacol 1991; 201: 121-2.
38 Lazaro-Ibanez GG, Torres-Lopez ]E, Granados-Soro V: Participation of the nitric oxide-cyclic GMP-ATP-sensitive K( +) channel pathway in the antinociceptive action of ketorolac. Eur] Pharmacol 2001; 426: 39-44.